Digi International Expands Industry-Leading Portfolio of Connectivity Solutions for Private Cellular Networks, Supporting Transmission and Distribution for Utilities
7.2.2023 16:00:00 EET | Business Wire | Press release
Expanding its portfolio of solutions to support private cellular networks, Digi International (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) solutions, connectivity products, and services, today launched new versions of its widely adopted Digi IX10 cellular router at DistribuTECH 2023. The new solution enables electric utilities to deploy private cellular networks that leverage the CBRS Band 48 shared spectrum or Anterix Band 8 900 MHz licensed spectrum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005387/en/
Digi supports private networks in collaboration with third-party providers. (Photo: Business Wire)
Building upon its expansive portfolio of Private Cellular Network (PCN) enabled devices, Digi IX10 is a full-featured cellular router combining trouble-free reliability with long service life. Flexible power and connectivity options make it a versatile and cost-effective choice for electric utilities, smart-grid equipment manufacturers, and other stakeholders that need to secure critical infrastructure data transmission over private cellular networks — including variants for Anterix 900 MHz licensed spectrum and CBRS 3.5 GHz spectrum.
“In the utilities market, private broadband is rapidly emerging as a must-have for grid modernization efforts,” said Carlos L'Abbate, CTO from Anterix. “As the nation’s largest holder of licensed spectrum in the 900 MHz band, our Anterix Active Ecosystem welcomes Digi’s latest addition to its portfolio of PCN-enabled routers. Together, Digi and Anterix are uniquely positioned to help utilities achieve secure, resilient and customer-controlled operations.”
The new Digi solution is ideal for a range of use cases in the industrial and utilities sectors, including transmission and distribution automation, connecting grid assets, metering, power quality monitoring, and remote instrumentation, as well as EV charging, solar farms, and other utilities applications that require greater intelligence, visibility, and edge computing.
“When it comes to modernizing our grid infrastructure, connectivity remains among the most important requirements,” said Kinana Hussain, Vice President of Product Management, from Digi International. “The latest model of the Digi IX10 expands our PCN device portfolio and, coupled with Digi Remote Manager, reaffirms our commitment to providing the smart and affordable connectivity needed by stakeholders in the electric utilities industry.”
Digi’s PCN solutions feature Digi Remote Manager® (Digi RM), the command center enabling the orchestration, management, and visibility of PCN devices. Digi RM enables low/no-touch provisioning, mass configuration, maintenance, and support, even for thousands of devices. With Digi RM, utilities can evaluate, update, and configure Digi devices while gaining visibility into network health. Digi also offers an on-premise remote management option for deployments requiring full control, and customization of their networking infrastructure.
“Digi International has been a prominent member of the OnGo Alliance for many years,” said Alan Ewing, Executive Director of the OnGo Alliance. “The launch of the Digi IX10 for CBRS marks another milestone in the continued adoption of 4G LTE and 5G solutions using shared spectrum. This addition to the company’s broad portfolio of PCN solutions will offer utilities – and other companies as well – more deployment options as they strive to improve the resiliency of the nation’s grid infrastructure.”
IX10 Features & Benefits:
-
Design – Compact, economical and rugged, Digi IX10’s small footprint provides versatility in placement, and its specs ensure it can withstand broad temperature ranges, making it ideal for public or private cellular networks in harsh environments.
-
Flexibility – Wirelessly connects IP-based devices while protecting investments in legacy serial devices. Flexible power input and low-power consumption allows it to use existing DC power in control cabinets, as well as solar for remote installations.
-
Reliability – Redundant connectivity with dual SIMs and Digi SureLink® for failover from private to public networks, or dual-public networks.
- Security - Built-in Digi TrustFence® for device security, device identity and data privacy.
For pricing information, contact Digi International.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005387/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom